A liver-infiltrating CD4+ Tfh1 cell response predicts HCV control, hepatitis, and seroconversion during acute infection
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci178089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Heather Blasczyk und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Hepatitis C, Hepacivirus, Liver, T Follicular Helper Cells. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Sustained CD4+ T cell immunity is required for resolution of acute hepatitis C virus (HCV) infection, but the response remains poorly characterized. Here, circulating CD4+ T cells with high programmed cell death 1 (PD-1) and ICOS coexpression were temporally associated with onset of virus control, seroconversion, and hepatitis in HCV-infected chimpanzees. Coproduction of T follicular helper (Tfh) (IL-21 and CXCL13) and Th1 (IFN-γ and TNF) cytokines after stimulation with HCV nonstructural proteins demonstrated that the response was predominately Tfh1 like and virus specific. Transcriptional analysis verified a Tfh1 lineage assignment. Effector-related genes such as ADGRG1 (GPR56), ZNF683 (Hobit), and KLRB1 (CD161) were also expressed. HCV-specific PD-1hiICOShi CD4+ Tfh1-like cells were enriched in liver, suggesting the potential for B and CD8+ T cell help at the site of virus replication. Most circulating and intrahepatic PD-1hiICOShi CD4+ Tfh1-like cells did not express CXCR5 and therefore resembled CXCR5-CXCL13+ peripheral helper cells that infiltrate tumors and tissues inflamed by autoimmunity. PD-1hiICOShi CD4+ Tfh1-like cells also peaked after hepatitis A virus infection, but the response was accelerated by several weeks compared with HCV infection. The PD-1hiICOShi phenotype and temporal association between the peak response and alanine aminotransferase may provide markers to guide human studies of CD4+ T cell immunity against HCV and other hepatotropic viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
- Texas Biomedical Research Foundation, San Antonio, Texas, USA.
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) and Département de Médecine, Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada.
- Emory Vaccine Center, Division of Microbiology and Immunology, Emory National Primate Research Center and Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, U…
- Department of Internal Medicine and.
- Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Förderung
- NIAID NIH HHS
- National Institutes of Health
- Canadian Institutes of Health Research
Zitieren
APA
Blasczyk, H., Bremer, W., Phelps, C. C., Zhou, Y., Bowen, D. G., Xu, Z., Lanford, R., Shoukry, N. H., Grakoui, A., Skinner, N., & Walker, C. M. (2025). A liver-infiltrating CD4+ Tfh1 cell response predicts HCV control, hepatitis, and seroconversion during acute infection. Journal of Clinical Investigation. https://doi.org/10.1172/jci178089
Vancouver
Blasczyk H, Bremer W, Phelps CC, Zhou Y, Bowen DG, Xu Z, et al. A liver-infiltrating CD4+ Tfh1 cell response predicts HCV control, hepatitis, and seroconversion during acute infection. Journal of Clinical Investigation. 2025. doi:10.1172/jci178089
BibTeX
@article{Blasczyk2025,
author = {Blasczyk, Heather and Bremer, William and Phelps, Christopher C and Zhou, Yan and Bowen, David G and Xu, Zhaohui and Lanford, Robert and Shoukry, Naglaa H and Grakoui, Arash and Skinner, Nicole and Walker, Christopher M},
title = {A liver-infiltrating CD4+ Tfh1 cell response predicts HCV control, hepatitis, and seroconversion during acute infection},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci178089}
}
EUVIMED